AIM
KYNB

Aigen Investment Management’s Kyntra Bio KYNB Stock Holding History

Aigen Investment Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,766
Closed -$254K – 910
2023
Q2 		$254K Buy
+3,766
New +$1.56M 0.04% 544
2021
Q4 		– Sell
-1,388
Closed -$355K – 1078
2021
Q3 		$355K Buy
+1,388
New +$492K 0.07% 307
2020
Q4 		– Sell
-231
Closed -$237K – 857
2020
Q3 		$237K Sell
231
-131
-36% -$141K 0.03% 597
2020
Q2 		$367K Buy
+362
New +$336K 0.05% 552
2020
Q1 		– Sell
-90
Closed -$96K – 1356
2019
Q4 		$96K Buy
+90
New +$91.9K 0.02% 690

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aigen Investment Management's KYNB Position: Q3 2023 in Review

Aigen Investment Management sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 3,766 shares — an estimated $254K sold.

Aigen Investment Management first reported a position in KYNB in Q4 2019 and held it in 5 quarters. The position peaked at $367K in Q2 2020. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • Aigen Investment Management reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • Aigen Investment Management sold 3,766 Kyntra Bio shares in Q3 2023, an estimated $254K.
  • Aigen Investment Management first reported a position in Kyntra Bio in Q4 2019 and held it in 5 quarters.
  • Aigen Investment Management's Kyntra Bio position peaked at $367K in Q2 2020.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Aigen Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.